AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

At STAT's Breakthrough Summit East, the CEOs of Ro and Included Health said the the U.S. health care system poses obstacles ...

The phase 3 trial success over Lilly’s Trulicity (dulaglutide), an already-marketed GLP-1 class rival, further bolsters semaglutide's profile ahead of its anticipated approval later this year as ...

However, TD Cowen projects diabetes and obesity to account for 59% and 41% of the GLP-1 sales in 2030, respectively, and LLY to take roughly 48% share of the market just ahead of NVO’s 45% share ...

Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...

Unlike Lilly’s injectable GLP-1 currently on the market, tirzepatide, orforglipron is an oral medication. The drug has already turned in positive phase 2 data in obesity and is expected to ...

Lilly’s chances of leading the GLP-1 race long-term are higher, but investors should brace for volatility if competition intensifies or regulators crack down on pricing. The edge Eli Lilly has ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

Roche is in-licensing co-development and co-commercialization rights to Denmark’s Zealand ... GLP-1 drugs ruling the obesity space. The GLP-1 space is dominated by NVO and Eli Lilly LLY, with ...

Eli Lilly launches Mounjaro in India addressing diabetes-obesity crisis. Approved by CDSCO yet high costs limit accessibility ...

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as it would be easier to manufacture and distribute globally.